WILMINGTON, Del.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq: INCY) today announced that it has created two new units to better position the organization for future growth in the U.S. and internationally. One of these is a U.S. country organization that will lead commercial and medical affairs in the United States. In the future, the company expects to establish other similar country- or regionally-based organizations. The other new unit is a Global Product Strategy and Business Development & Licensing (BD&L) unit that will lead global competitive strategies for Incyte’s expanding portfolio beyond Jakafi® (ruxolitinib), as well as review business development opportunities.

“Jim created significant commercial momentum for Incyte. We sincerely thank him for all his efforts, including driving towards our goals for Jakafi, and we wish him well”

Jim Daly has indicated he will leave Incyte later this month, and commented, “My decision to return to California was a personal one. I leave Incyte knowing that the business is performing well and that the team is well-prepared to grow Jakafi, and to advance Incyte’s pipeline of innovative medicines, as the company seeks to make a major difference for cancer patients in the years ahead.”

Barry Flannelly, Pharm. D., has been appointed to the newly created position of Executive Vice President and General Manager U.S., effective immediately. The existing U.S. commercial team, including those responsible for Jakafi, remains intact and will now report into Dr. Flannelly. A newly created position of Head of Global Product Strategy and BD&L is expected to be filled in the near future.

“Jim created significant commercial momentum for Incyte. We sincerely thank him for all his efforts, including driving towards our goals for Jakafi, and we wish him well,” stated Hervé Hoppenot, Incyte’s President and Chief Executive Officer. “Incyte has a large development portfolio and significant global opportunities, and now is the opportune time for us to organize the company to include both a regional operating unit for the U.S. as well as a global strategic product team. We are also delighted to be able to immediately move Barry into his new role and draw on his more than 20-year track record in the biopharma industry.”

Barry has been working in oncology since 1987, and began his career in the pharmaceutical and biotech industry at Rhone-Poulenc Rorer, which later became Sanofi-Aventis. He has since had roles of increasing responsibility at Novartis, Abraxis Oncology, Onyx Pharmaceuticals and Nektar Therapeutics. During his career, he has held positions in medical affairs, strategic planning, commercial operations, including head of sales and head of marketing, and business development. He earned his Doctor of Pharmacy from the University of Maryland School of Pharmacy, his Master in Business Administration from the University of Baltimore and his Bachelor of Science in Pharmacy from Massachusetts College of Pharmacy.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. For additional information on Incyte, please visit the Company’s website at www.incyte.com.

Source: BioSpace Featured News